Covetrus, Inc. (NASDAQ:CVET) Insider Dustin Finer Sells 1,500 Shares

Covetrus, Inc. (NASDAQ:CVET) insider Dustin Finer sold 1,500 shares of Covetrus stock in a transaction dated Tuesday, June 8th. The shares were sold at an average price of $27.86, for a total value of $41,790.00. Following the completion of the sale, the insider now owns 36,710 shares of the company’s stock, valued at approximately $1,022,740.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Dustin Finer also recently made the following trade(s):

  • On Wednesday, June 2nd, Dustin Finer sold 2,322 shares of Covetrus stock. The shares were sold at an average price of $27.28, for a total value of $63,344.16.
  • On Tuesday, May 4th, Dustin Finer sold 1,500 shares of Covetrus stock. The stock was sold at an average price of $30.43, for a total value of $45,645.00.
  • On Tuesday, April 6th, Dustin Finer sold 1,500 shares of Covetrus stock. The stock was sold at an average price of $29.38, for a total value of $44,070.00.

NASDAQ CVET opened at $27.83 on Friday. The stock has a market cap of $3.80 billion, a PE ratio of -347.83, a PEG ratio of 1.74 and a beta of 2.05. Covetrus, Inc. has a fifty-two week low of $15.03 and a fifty-two week high of $40.78. The business has a 50 day moving average of $28.18. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.27 and a current ratio of 2.09.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Rockefeller Capital Management L.P. boosted its holdings in Covetrus by 7,326.7% in the 1st quarter. Rockefeller Capital Management L.P. now owns 1,114 shares of the company’s stock worth $33,000 after acquiring an additional 1,099 shares during the period. Assetmark Inc. raised its position in shares of Covetrus by 25.2% in the 4th quarter. Assetmark Inc. now owns 2,075 shares of the company’s stock valued at $60,000 after purchasing an additional 417 shares in the last quarter. Annapolis Financial Services LLC acquired a new position in shares of Covetrus in the 4th quarter valued at approximately $77,000. Peconic Partners LLC acquired a new position in shares of Covetrus in the 4th quarter valued at approximately $86,000. Finally, Veriti Management LLC acquired a new position in shares of Covetrus in the 4th quarter valued at approximately $94,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

CVET has been the subject of a number of research reports. Zacks Investment Research upgraded Covetrus from a “sell” rating to a “hold” rating in a report on Thursday, May 20th. Barclays initiated coverage on Covetrus in a report on Wednesday, February 17th. They set an “overweight” rating and a $48.00 target price for the company. Finally, Raymond James boosted their target price on Covetrus from $31.00 to $39.00 and gave the stock an “outperform” rating in a report on Tuesday, March 2nd. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $33.40.

Covetrus Company Profile

Covetrus, Inc, together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers.

Further Reading: Special Dividends

Insider Buying and Selling by Quarter for Covetrus (NASDAQ:CVET)

Receive News & Ratings for Covetrus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covetrus and related companies with MarketBeat.com's FREE daily email newsletter.